Cumberland Pharmaceuticals
CPIX
22 hedge funds and large institutions have $5.62M invested in Cumberland Pharmaceuticals in 2022 Q2 according to their latest regulatory filings, with 1 funds opening new positions, 7 increasing their positions, 10 reducing their positions, and 5 closing their positions.
1.19% less ownership
Funds ownership: 19.53% → 18.34% (-1.2%)
15% less funds holding
Funds holding: 26 → 22 (-4)
30% less repeat investments, than reductions
Existing positions increased: 7 | Existing positions reduced: 10
31% less capital invested
Capital invested by funds: $8.17M → $5.62M (-$2.55M)
80% less first-time investments, than exits
New positions opened: 1 | Existing positions closed: 5
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Prudential Financial
Newark,
New Jersey
|
+$23.8K |
| 2 |
BAM
Berkshire Asset Management
Wilkes Barre,
Pennsylvania
|
+$16K |
| 3 |
Geode Capital Management
Boston,
Massachusetts
|
+$5.74K |
| 4 |
TRCT
Tower Research Capital (TRC)
New York
|
+$4.66K |
| 5 |
BlackRock
New York
|
+$3.11K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Two Sigma Advisers
New York
|
-$160K |
| 2 |
Two Sigma Investments
New York
|
-$86.9K |
| 3 |
Bank of New York Mellon
New York
|
-$56K |
| 4 |
Renaissance Technologies
New York
|
-$52.1K |
| 5 |
Arrowstreet Capital
Boston,
Massachusetts
|
-$50K |
CPIX Hedge Fund Activity: Q2 2022 in Review
22 of the 5,936 institutional investors tracked by Wall St. Rank reported a position in Cumberland Pharmaceuticals (CPIX) for Q2 2022, worth a combined $5.62M — down 31% from $8.17M a quarter earlier.
Sellers outnumbered buyers: 5 funds closed out of CPIX and 1 opened new positions — a net loss of 4 holders — while 10 trimmed existing stakes and 7 added.
The largest buyer was Prudential Financial, opening a new position worth an estimated $23.8K. The largest seller was Two Sigma Advisers, cutting an estimated $160K.
- 22 institutional investors held Cumberland Pharmaceuticals (CPIX) as of Q2 2022, down from 26 in Q1 2022.
- Funds reported $5.62M of Cumberland Pharmaceuticals stock for Q2 2022, down 31% quarter-over-quarter.
- 1 fund opened new Cumberland Pharmaceuticals positions in Q2 2022 and 5 closed out, a net change of -4 holders.
- The largest Cumberland Pharmaceuticals buyer in Q2 2022 was Prudential Financial, an estimated $23.8K added.
- The largest Cumberland Pharmaceuticals seller in Q2 2022 was Two Sigma Advisers, an estimated $160K sold.
Based on aggregated 13F filings for Q2 2022.